• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

FDA mandates new labels for anti-fungals

Article

Miami - The FDA last month issued a health warning concerning two popular anti-fungal drugs used to treat onychomycosis, requiring that labels for Sporanox (Janssen Pharmaceuticals) and Lamisil (Novartis) carry stronger warnings about potential liver damage. Sporanox also must warn against potential heart disease, the administration said.

Related Videos
Related Content
Addressing Disparities in Skin-Aging Prevention Among Women of Color

Addressing Disparities in Skin-Aging Prevention Among Women of Color

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study

Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients

Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients

Article
Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers

Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers

Article
© 2024 MJH Life Sciences

All rights reserved.